Maladie de Parkinson : Servier et Oncodesign annoncent la sélection d’un candidat préclinique
Initiée en mars 2019, cette collaboration de Recherche et Développement porte sur la découverte d’inhibiteurs de la kinase LRRK2 issus de la plateforme Nanocyclix®, propriété d’Oncodesign, et sur leur action comme agents thérapeutiques potentiels contre la maladie de Parkinson.
IMAkinib® program is an innovative approach, based on Nanocyclix® chemistry technology, which aims to develop new Tyrosine Kinase Inhibitors (TKIs) radiotracers used for Positron Emission Tomography (PET). The epidermal growth factor receptor (EGFR) is an established target for the treatment of advanced non-small cell lung cancer (NSCLC). TKIs targeting EGFR are used widely in clinic; unfortunately, the majority of patients develop a resistance to the TKI. TKI PET-imaging can provide a tool to determine and predict the activity of EGFR and the responsiveness to EGFR TKI. We put in place an efficient workflow to develop new [18F] PET radiotracers from radiochemistry of compounds to clinical PET imaging. Based on our studies, we demonstrated that our EGFR targeted radiotracer is a good candidate to evaluate the EGFR activity in NSCLC using PET imaging.
More about Cyril Berthet, Discovery Program Director, Oncodesign
Cyril Berthet is a Discovery Program Director at Oncodesign. He holds a PhD in Molecular and Cellular Biology from the University of Lyon, France. In 2002, he joined the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, US as a Research Associate. He joined Oncodesign in 2007 as a project leader and now manages strategic partnerships in therapeutic and biomarker discovery. He is particularly involved in pharmaco-imaging R&D programs and leads the Pharmimage consortium.
18 rue Jean Mazen - FR - 21000 Dijon Tél.+33 380 788 260